Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/
pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study
will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2
expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/
pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.